Jessica Davis Pluess

Journalist @swissinfo_en covering multinationals, #bigpharma, biotechs, workplace. Bay Area native in Switzerland. Circus performer in another life.

[Jessica Davis Pluess @JPluess]

First two stories from Kenya on what it takes to get “innovative medicines” for cancer and genetic diseases to the world. Price is clearly not the only barrier to access life-saving medicine but it’s a big one. More on this: https://t.co/lLRIZnxsSL

[swissinfo.ch @swissinfo_en]

As the pharma industry turns away, parents of children with ultra-rare diseases step in to advance drug development. But the funding challenges are immense even in a wealthy country like Switzerland. https://t.co/wTTfz89M7K #rarediseases #genetherapy

[swissinfo.ch @swissinfo_en]

The World Health Organization (WHO) member states recognised rare diseases as a global health priority for the first time. What does this mean and how could it impact access to life-saving treatment for the millions of people with rare diseases? #WHA78 https://t.co/rCHWxjm0Nt

[swissinfo.ch @swissinfo_en]

Swiss pharma giant Novartis is diving into research on ageing to tap the growing, and potentially lucrative, market for drugs that help keep older adults healthy. #longevity #drugdevelopment #pharmaceuticals https://t.co/2OlrT8Tn4C

[swissinfo.ch @swissinfo_en]

United States President Donald Trump has taken aim at European governments for what he sees as undercharging for medicine at the expense of US patients. But raising prices in Europe would face pushback from lawmakers and the public. https://t.co/uFhb9asmvR

[swissinfo.ch @swissinfo_en]

Over 30 years ago Michael Hall, a molecular biologist at @UniBasel_en, made a groundbreaking discovery of the gene Target of Rapamycin, or TOR. Today his seminal work is fuelling one of the fastest growing areas of healthcare research – longevity. 👉 https://t.co/e9JjbzvoAR

[swissinfo.ch @swissinfo_en]

With growing uncertainty in US financial markets and research funding, Chinese companies are swooping in to present themselves as stable, open partners to the Swiss biotech sector. https://t.co/rZObyvKLe4

[swissinfo.ch @swissinfo_en]

Michael Hall, a molecular biologist at the University of Basel, is a virtual unknown in today’s social media longevity scene. But his discovery of the gene Target of Rapamycin (TOR) is behind one of the most promising longevity drugs. #health #science https://t.co/4U6thPrwcL

[swissinfo.ch @swissinfo_en]

Are longevity clinics just hype or are they the secret to living a longer, healthier life? We visited some longevity clinics in Switzerland to probe the science behind the marketing brochures. Here's what we found out. #longevity #healthspan #health https://t.co/5C54EKme4o

[swissinfo.ch @swissinfo_en]

Faced with a lack of breakthroughs in treating #mentalhealth disorders, older methods like electrical-based therapies are making a comeback — including in #Switzerland. This revival is reshaping approaches in #psychiatry and mental health treatment. https://t.co/DWXm1gQt07

[swissinfo.ch @swissinfo_en]

Community pharmacies in many parts of the world are disappearing but not in Switzerland. Why is that? And, what does the future hold for Swiss pharmacies? https://t.co/onOMMDDENu

[swissinfo.ch @swissinfo_en]

In rich places like Switzerland, you wouldn’t generally expect your pharmacist to tell you they’ve run out of painkillers. But shortages of all types of medicines are becoming an issue. Is the situation similar where you are? Let us know. https://t.co/eKAuieZeBw

[swissinfo.ch @swissinfo_en]

Last year, Swiss health insurance companies spent CHF9 billion ($10.2 billion) on medicine for compulsory insurance, almost 6% more than in the previous year. And more than ever before. https://t.co/qUJW2cBGfH

[swissinfo.ch @swissinfo_en]

Representatives of the scientific community warned against banning animal testing, arguing it would compromise important research, particularly in the biomedical field. https://t.co/xWcz2Bqrrt

[swissinfo.ch @swissinfo_en]

Switzerland consistently tops rankings of the most innovative countries, surpassing tech powerhouses like the United States and China. Why does it keep outpacing peers? #innovation #biotech https://t.co/woTzgkq9ys

[swissinfo.ch @swissinfo_en]

A second Trump presidency could be a boost for biomedical innovation, but it also risks eroding public trust in the pharmaceutical industry if science, trade and public health are sidelined. #bigpharma #globalhealth https://t.co/6eu1exfP6g

[swissinfo.ch @swissinfo_en]

September marks World #Alzheimer's month and we bring you a story about the first new drug for Alzheimer’s disease in two decades: #Leqembi. @Swissmedic_ is expected to decide by the end of the year whether to approve this drug. ↩️ https://t.co/d1K0iW5uEV

[swissinfo.ch @swissinfo_en]

Medicine can affect women differently than men, but rarely are sex and gender considered in the development of drugs. There’s now a movement, including in Switzerland, to change this. https://t.co/rOhjOfIUwy

[swissinfo.ch @swissinfo_en]

For Swiss-based pharma giant Novartis, new US price-setting rules for ten major drugs are “not objective or transparent” and don’t reflect the true value of medicine. https://t.co/8aHoaRA7oK

[swissinfo.ch @swissinfo_en]

Japan is the world’s third-largest pharmaceutical market, but it is increasingly being overlooked by international drugmakers when launching new drugs. The government is now fighting back. https://t.co/rmXyQ8Pf6H

[STAT @statnews]

Medicare officials unveiled the results of the program’s first 10 drug price negotiations, despite the industry’s efforts to stop them. https://t.co/fPbQLeqcCy